Monitoring Uptake of a New Oncology Formulation Across NHS Trusts
A large pharmaceutical manufacturer is managing a mature oncology brand with multiple approved uses in the UK. As part of a lifecycle extension strategy, a new subcutaneous formulation was introduced alongside the established intravenous option.
Understanding how the new version was being adopted across the NHS was critical to forecasting, field focus and long-term positioning. Overall sales volumes alone were not sufficient to guide those decisions.
The Challenge
The company could see product volumes supplied to individual trusts, but lacked clarity on how usage was distributed across clinical settings and product versions. Insight was largely derived from internal sales intelligence and limited Freedom of Information responses.
Without structured prescribing data, planning decisions were shaped by partial visibility and working assumptions about how uptake was evolving.
Verpora Approach
Verpora’s VSTx Molecule Report VSTx Molecule Report provided a detailed breakdown of product use by both indication and formulation at trust level. Multiple data sources were integrated and aligned with the company’s own sales data to ensure consistency and reliability.
This report provided the foundation for a structured view of how the subcutaneous formulation was being adopted, and how usage patterns differed across indications and geographies.
Client Impact
The client gained clear visibility of where and how their product was being used, by indication and formulation. Early adopters of the subcutaneous version were identified, allowing lessons from those trusts to be examined and incorporated into brand strategy.
Assumptions formed through internal intelligence and market research were tested against prescribing data, revealing that some patterns held true only in specific trusts rather than consistently across the country.
“We were able to see what was really happening (or not) within each trust . Sharing this data with the account teams has allowed to account plan in a much more precise way than they could before access to the VSTx report”
Strategic Finance & Insights Lead
Key Takeaway
In complex, multi-indication markets, internal data sources and field intelligence can naturally shape a coherent view of uptake. However, those sources do not always provide segmentation by clinical use and product version.
By introducing structured prescribing data, the client was able to test its understanding of market behaviour more fully. Some assumptions were confirmed; others required adjustment. With clearer segmentation came more precise forecasting, more targeted resource allocation and greater confidence in how the lifecycle strategy was evolving.
